Benjamin Young, M.D., Ph.D.
Dr. Young is the senior vice president and chief medical officer of the International Association of Providers of AIDS Care (IAPAC), one of the world's largest organizations of HIV health care providers, where among his responsibilities, he coordinates educational projects for healthcare providers in Africa and Latin America. He is the medical editor for IAPAC's widely read AIDSinfonet.org. He is also an adjunct professor at the Korbel School of International Studies at the University of Denver. Dr. Young provides care for people living with HIV at APEX Family Medicine in Denver.
The much-traveled Dr. Young is a long-term resident of Colorado's Rocky Mountains, but was raised in New York and San Diego. Dr. Young began his graduate studies at the University of Colorado in Boulder, where he received a Ph.D. in molecular biology and biochemistry working in the laboratory of Nobel laureate Thomas Cech. He went on to earn his medical doctorate in 1992 from the University of Colorado School of Medicine and completed his post-graduate training in internal medicine and infectious diseases at the University of Colorado.
Dr. Young is the author of more than 80 journal articles, reviews and book chapters relating to HIV and its treatment. He is a member of the World Health Organization's HIV Clinical Guideline Development Group and principal investigator with the U.S. Centers for Disease Control and Prevention's HIV Outpatient Study (HOPS), a massive ongoing analysis of the health of HIV-positive people throughout the U.S. A member of the HIV Medicine Association, the International AIDS Society and the American Academy of HIV Medicine, Dr. Young is also actively involved in educating health care professionals and community groups throughout the world on HIV-related subjects. He has devoted previous years to training HIV physicians in Eastern Europe and Central Asia, where he witnessed a coup d'etat and a polio epidemic.
Dr. Young has received consulting or speaking fees from Bristol-Myers Squibb, Gilead Sciences, Merck & Co. and ViiV Healthcare. His research group has received research funding from Gilead Sciences, Merck & Co. and ViiV Healthcare. (Disclosures were last updated January 2016.)